CD34+hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., Turgut M., AKSU S., SAYINALP N., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, sa.8, ss.1851-1856, 2020 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/sag-2001-173
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1851-1856
  • Anahtar Kelimeler: Multiple myeloma, CD34(+) hematopoietic progenitor cell, engraftment, survival, BLOOD, MOBILIZATION, GUIDELINES, MANAGEMENT, COLLECTION, DIAGNOSIS, LYMPHOMA
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34(+) hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 x 10(6)/kg. The aim of this study was to evaluate the relationship between the dose of CD3V4(+). HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.